The company plans to open a $20 million Series C round in Q2 of this year and launch a study to support a US Food and Drug Administration submission in mid-2018.
The study will involve assaying proteomic markers for dementias including Alzheimer's disease, and understanding genomic markers as part of the normal aging process.
The researchers believe that by monitoring mtDNA copy number in blood, they will be able to identify people at risk for developing CHD who could benefit from preventative efforts.
Multi-omics, mass spec-based imaging, and cardiovascular biomarkers received extra attention at MSACL US while small molecules continue to drive the field.
In a new AMP working group project, labs can volunteer to compare their interpretation of challenging variants to help identify where and how the guidelines might be improved.
The effort aims to identify a suite of markers that could aid in management of type II diabetes and related conditions like retinopathy and kidney damage.
Investigators plan to expand the program nationwide, with the hope that it can help guide care for living family members and further understanding of causal diseases.
The company has signed an agreement with a hospital group in Northern California and will be offering its test, named StatRes, at the group's seven facilities.
Some six months after establishing itself as an independent entity, the company plans to roughly double its protein biomarker libraries by the end of the year.
